Email
Print
Market Overview:
The Antisense Oligonucleotides Market size is estimated to reach $5.3 Billion by 2031, growing at a CAGR of 6.6% during the forecast period 2025-2031, according to a recent report published by IndustryARC, titled, “Antisense Oligonucleotides - By Type (CpG oligonucleotides, Eteplirsen, Nusinersen, Fomivirsen, Givosiran, and Others), By Application (Neurodegenerative diseases, Cancer, Hearing loss, Genetic Disorder, and Others), By Route of Administration (Parenteral, Oral, and Others), By End Use Industry (Pharmaceutical, Healthcare, Research Institute, and Others), By Geography Analysis - Global Opportunity Analysis & Industry Forecast, 2025-2031”.
Increasing cases of neurological diseases, progressing Antisense Oligonucleotides innovations and ASO research, personalized medicine and targeted therapeutics are fueling the growth of the Antisense Oligonucleotides industry during the forecast period 2025 – 2031.
North America Dominated the Market in 2024
North America accounted for the largest share in the Antisense Oligonucleotides Market in 2024. North America leads in strong research initiatives, advanced biotechnology infrastructure, and high adoption of gene-targeted therapies ensuring patient safety for quicker relief. With the (U.S Food and Drug Association) FDA’s continued support, the United States plays a key role in ASO-based treatments, like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and Qalsody (tofersen) for ALS. In October 2024, with the support of Invest Ontario, OmniaBio built a new biomanufacturing facility in Hamilton with an overall project investment of over $580 billion, creating 250 skilled jobs for gene therapies. This project promises to revolutionize the treatment of a broad range of life-threatening diseases such as cancer, autoimmune diseases, neurological disorders, and numerous genetic conditions.
Antisense Oligonucleotides Market: Key Takeaways
Personalized Medicine and Targeted Therapeutics
Antisense Oligonucleotides (ASOs) are setting an example in personalized medicine by enabling targeted gene blocking for precise disease management. These personalized medicines offer customized formulations to an individual's genetic profile, making them highly effective for rare genetic disorders, neurodegenerative diseases, and cancers instead of conventional and regular treatments. In February 2025, according to a research study by Genomics England, almost 90% of people in England would agree to genetic testing to get the most effective medication and reduce the risk of side effects which aligns with the concept of personalized medicine, where treatments are customized based on a person's genetics. This increasing level of acceptance in the public led to an initiative launched by the government, the Rare Therapies Launch Pad, that will develop a pathway for children with rare conditions to access individualized therapies.
For More Queries About "Antisense Oligonucleotides Market " @ https://www.industryarc.com/reports/request-quote?id=800897
The Rise in Neurological Cases
It is observed that rising consistent number of neurological cases is the significant driver for the Antisense Oligonucleotides Market. Additionally, conditions such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Huntington’s disease, and Alzheimer’s are on the rise, further fueling the demand for targeted gene therapies aligning with the rise of Antisense Oligonucleotides Market’s growth. In October 2023, according to a study by the World Federation of Neurology, neurological disorders are currently the second-highest cause of death and the leading cause of disability worldwide. The study also unveils that over 40% of the global population currently suffers from some kind of neurological condition, and this burden is projected to nearly double by 2050.
Scope of the Report:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recent Developments:
• In December 2024, GondolaBio and n-Lorem Foundation announced a collaboration to discover novel antisense oligonucleotide (ASO) medicines for patients who are not currently served by available treatment options.sa
• In October 2024, Resalis Therapeutics secured a strategic equity investment from Sanofi to advance its lead candidate, RES-010, into a Phase 2 clinical trial. RES-010, a first-in-class antisense oligonucleotide, targets miR-22, a key regulator in obesity-related pathways. This investment strengthens Resalis' position in developing next-generation metabolic disease therapies.
Antisense Oligonucleotides Market: Competitive Landscape
Key companies profiled in the Antisense Oligonucleotides Market are Alnylam Pharmaceuticals, Isis Pharmaceuticals, Geron Corp, Biogen, NS Pharma, Inc, Jazz Pharmaceuticals, Swedish Orphan Biovitrum AB, Sarepta Therapeutics, Ionis Pharmaceuticals, Novo Nordisk A/S and Others
Related Reports:
Neurodegenerative Disease Market - The Neurodegenerative Disease Market Size is forecast to reach $ 55204 Million by 2030, at a CAGR of 3.90% during forecast period 2024-2030. Neurodegenerative diseases are a set of brain disorders that cause the structure and function of neurons in the central nervous system (CNS) and peripheral nervous system (PNS) to deteriorate over time (PNS).
Movement Disorder Market - The Movement Disorder Market size is estimated to reach $11067 Million by 2030, growing at a CAGR of 7.90% during the forecast period 2024-2030. Movement disorders are neurological diseases and syndromes affecting the ability to generate and control movement.
Personalized Medicine Market - Personalized Medicine Market Size is forecast to reach $ 555280 million by 2030, at a CAGR of 8% during forecast period 2024-2030.Personalized medicine is drugs prepared based on the response produced by the patient suffering from a particular disease and carry certain biomarkers to cater the requirement of an individual patient.
About IndustryARC™:
IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.
IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.
Contact Us:
Mr. Venkat Reddy
IndustryARC
Email: [email protected]
USA: (+1) 518-282-4727